2020 Revision to the guidelines for the management of myeloproliferative neoplasms.

In 2016, the World Health Organization (WHO) revised the diagnostic criteria of myeloproliferative neoplasms (MPNs) based on the discovery of disease-driving genetic aberrations and extensive analysis of the clinical characteristics of MPN patients. Recent studies have suggested that additional somatic mutations have clinical impacts on the prognosis of patients harboring these genetic abnormalities. Treatment strategies have also advanced with the introduction of JAK inhibitors, one of which has been approved for the treatment of myelofibrosis patients and hydroxyurea-resistant or intolerant polycythemia vera patients. Because recently developed drugs aim not only at hematologic responses but also at symptomatic and molecular responses, the response criteria were refined as well. Based on these changes, we have revised the guidelines by presenting the diagnosis, treatment, and risk stratification of MPNs that fit the reality in Korea.